Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD

Efficacy In Phase III Trial Exceeded Expectations

Executive Summary

Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

You may also be interested in...



Dupixent Heralds The Age Of Biologics In COPD

A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.

The Dealmaking Landscape According To Sanofi

Monika Vnuk, head of Sanofi’s business development, says the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.

The Dealmaking Landscape According to Sanofi

Monika Vnuk, head of Sanofi’s business development, tells Scrip that the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel